New startup ideas · Health and bio · Healthcare and bio
startup idea
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
- Marketplace
- Enterprise
- $100B+ market
- Creates a new category
- US first
5/5
venture judge
2
similar startups, last 2 years (9 all-time)
96%
of 3 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
97
Idea Score, 0-100 · raw 59.0 x 1.64
Warm
competition: more crowded than 32% of ideas · headwind x0.84
+3.4
government priorities, secondary (28 matching grants)
Trend
63
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)61
- Rounds announced 2025+ in the sector68
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
52
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)75
- Operator judge: real pain50
100x potential
89
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge100
- Market size axis100
- Moat axis80
- Neighbours still alive81
- Technologist judge75
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were licensed, gmp, manufacturing, bays, personalized, therapies, sold, bookable.
The idea in full
- What
- Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations. Each bay is qualified once by Bayworks and then added to a sponsor's filing as a licensed site, so a sponsor with a per-patient therapy can add capacity near the patient in weeks rather than building its own plant. Enterprise pharma and clinical-stage biotech pay a booking fee plus per-batch run fees; hospital and CDMO partners take a share of the slot revenue.
- Why now
- The current YC batches are full of per-patient biologics that cannot use conventional batch plants: Gamgee on scalable personalised cancer treatment, RonanRx Inc. personalizing peptides to individual biology, TareBio promising vaccines for any cancer or infection in weeks, and FinalDose on programmable DNA drugs; meanwhile Ambrosia Biosciences raised a $100M Series B on 2026-03-31, which is the size of check that goes into physical capacity.
- Wedge: first customer and entry point
- One academic medical center with an underused GMP suite plus three clinical-stage cell therapy sponsors: qualify a single bay, sell twenty booked batches, and use that filing package as the template for every subsequent bay.
- Path to 100x
- Biologics and cell and gene manufacturing is a $100B+ spend that is currently sold as bespoke long-term contracts, and turning it into bookable, pre-licensed capacity creates a category the way cloud compute did for servers. Every qualified bay makes the next sponsor faster to onboard, and the accumulated regulatory filings and site licenses are the moat, because a competitor must repeat inspection and qualification bay by bay.
- Ceiling
- If personalized therapies stay in small trials, total booked batch volume stays too low to fill the capital-heavy bay network and the business settles into being a regional CDMO.
- Closest real companies, as the generator saw them
- AbInitio Bio sells an intelligence layer for drug manufacturing as software, while Bayworks owns the licensed physical bay and the booking transaction. Ruma Care runs the operations stack for biologic infusion clinics at the delivery end; Bayworks sits one step upstream, at the point where the dose is made.
- Main risk
- Regulators treat each bay as a distinct site requiring full sponsor-specific inspection, which kills the fungibility the marketplace depends on.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
5/5
Pre-qualified bays turn a $100B+ bespoke contract market into bookable capacity, and each accumulated FDA filing compounds into a moat competitors must rebuild bay by bay.
Bootstrapper
1/5
Building FDA-registered cleanroom bays inside hospitals is nine figures of capital and per-site inspection before a single batch fee lands.
Operator
3/5
Sponsors already pay for suite reservations, but the whole thesis needs regulators to treat a qualified bay as fungible across filings.
Technologist
4/5
Qualifying a bay once and porting that filing package to each sponsor is years of regulatory engineering no weekend clone reproduces.
Risk
3/5
Owns its FDA site licences, but the stated risk is real: sponsor-specific inspection per bay makes the marketplace's fungibility a single regulatory assumption.
trends
2/5
The per-patient therapy manufacturing crunch is real but was known in 2023, and bookable GMP capacity needs no 2025-2026 trigger to exist.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (licensed, gmp, manufacturing, bays, personalized, therapies, sold, bookable): 9 all-time, 2 from the last two years. Same matching as Idea Check.
We use AI to personalize peptides to your biology
AI technical support for complex physical products
AI-assisted behavioral health
Nationwide virtual ABA therapy for autism.
Democratizing gene therapy by reinventing its manufacturing and…
We've transformed traditional therapy into an experience that is…
OrthoSens provides battery-free sensors that implant manufacturers embed directly into their standard implants, turning them into a connected, data-generating and recurring revenue asset
Synplogen is a company that brings together unique DNA synthesis technologies that Kobe University and others have been developing.
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
- AbInitio Bio ✓ 2026
- Ruma Care ✓ 2026
- Gamgee ✓ 2026
- Ambrosia Biosciences
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1127
startup-relevant grants in Healthcare and bio
$590M
awarded in the sector, tracked
130
opportunities open now in the sector
- Industrial production of milk extracellular vesicles for dual-use as a systemic radiotherapeutic medical countermeasure and cancer adjuvant therapyawardhigh relevance
NIH / NCATS · SBIR phase II · $986K · posted 2026-07-01
NIH / NICHD · SBIR phase I · $301K · posted 2025-09-15
- In vivo CAR therapies for lupus treatment using selectively expressed genetic payloads in immune-cell-biased lipid nanoparticlesawardhigh relevance
NIH / NIAID · SBIR phase I · $307K · posted 2026-08-14
- Clinical development of the anti-fas ligand monoclonal antibody M3T01 for treatment of advanced cancersawardhigh relevance
NIH / NCI · SBIR phase II · $979K · posted 2026-08-11
- Development of an Ultra-Long-Acting, Self-Administered, Dolutegravir-Based Treatment Regimen for HIV-1 and HIV-HBV Co-infectionawardhigh relevance
NIH / NIAID · SBIR phase II · $998K · posted 2026-08-04
- SBIR Phase II: Ai-mediated Neurotechnology for Enhanced Access to Virtual and Physical Realityawardhigh relevance
National Science Foundation · SBIR Phase II · $1M · posted 2026-08-04
- I-Corps: Translation Potential of a Robotic Hand Therapy System with Mirror-based Feedbackawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-07-24
- SBIR Phase II: AI-Driven Visualization of Rehabilitation Documentation to Support Decision-Making Across Care Settingsawardhigh relevance
National Science Foundation · SBIR Phase II · $1M · posted 2026-07-20
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 130 → 118 → 216 → 173 → 71 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 21 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 37 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- Marketplace
- Path to 100x
- Creates a new category
- Market size
- $100B+ market
- Capital intensity
- Capital-heavy (hardware, bio, infra)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Partners and channels
- Moat
- License or regulatory moat
- Geography
- US first
- Regulation
- Heavily regulated
- Vibe
- Boring business
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Health and bio · Healthcare and bio
Claimsmith
The agent platform where healthcare's back office gets rebuilt by everyone but us.
Claimsmith is a no-code platform where hospitals, billing companies, and health IT vendors build and run AI agents for administrative work: eligibility checks, prior authorization, claims appeals, and records chasing.
Fictional company written 2026-08-23 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.